Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease
In this real-world retrospective matched cohort study, PAD was not associated with increased toxicity or inferior oncologic outcomes. One in five patients with PAD experienced autoimmune flare, underscoring the need for close monitoring. These findings support ICI use in carefully selected lung cancer patients with PAD.
Authors
- Daniel E. Meyers (ORCID: https://orcid.org/0000-0002-7619-7327)
- Siddhartha Goutam (ORCID: https://orcid.org/0000-0002-5398-2357)
- Liam J. O’Neil (ORCID: https://orcid.org/0000-0001-5580-6472)
- David E. Dawe (ORCID: https://orcid.org/0000-0001-9762-3156)
- Arjun Athreya Raghavan
- Carrie Ye
- Hans Alday
- Jeffrey Graham
Institutions
- University of Alberta (CA)
- CancerCare Manitoba (CA)
- University of Manitoba (CA)
Publication Details
- Journal
- Lung Cancer
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1016/j.lungcan.2026.109347
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00